Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
Read More
We are working hard to bring novel targeted therapies to children with brain tumors and potentially others who can benefit.
Read More
Read More
Read More